Mode
Text Size
Log in / Sign up

8-year disease-free survival after surgery alone for clear cell adenocarcinoma of the urethraSurgery alone yields 8-year survival in rare urethral cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider surgery alone for select cases of clear cell adenocarcinoma of the urethra, but recognize evidence is limited to case reports.

This is a case report and literature review describing a 39-year-old woman diagnosed with clear cell adenocarcinoma of the urethra (CCAU), a rare malignancy. The patient underwent surgery alone, consisting of laparoscopic radical cystectomy, lymph node dissection, and cutaneous ureterostomy. The primary outcome was disease-free survival, and the patient remained recurrence-free for 8 years through January 2025. No adjuvant therapy was administered.

The authors highlight that this is one of the longest reported disease-free survivals for CCAU treated with surgery alone. The literature review contextualizes the case within the sparse evidence on this tumor type, where treatment approaches vary and outcomes are generally poor.

Limitations include the small sample size inherent to a case report, which precludes generalizability. No adverse events or safety data were reported. The findings should be interpreted cautiously and not extrapolated to the broader population of patients with CCAU.

For clinicians, this case underscores that radical surgery may achieve durable remission in select patients with localized CCAU, but treatment decisions must be individualized given the lack of comparative data.

A 39-year-old woman with a rare type of urethral cancer called clear cell adenocarcinoma (CCAU) had surgery alone and remained cancer-free for 8 years, according to a case report published in January 2025. The surgery included laparoscopic radical cystectomy, lymph node dissection, and cutaneous ureterostomy. No other treatments like chemotherapy or radiation were used.

This is a single case report, meaning it describes just one patient. The findings are encouraging for this particular person, but they may not apply to everyone with CCAU. The report did not mention any side effects or safety concerns from the surgery.

Because this is only one case, doctors cannot draw broad conclusions. More research with larger groups of patients is needed to know if surgery alone is a good option for most people with this cancer. For now, this report offers hope but does not change standard treatment.

If you or someone you know has CCAU, talk to a doctor about the best treatment plan. Every case is different, and what worked for one person may not work for another.

What this means for you:
One woman with a rare urethral cancer had no recurrence 8 years after surgery alone, but this is just one case.

Common questions

What is clear cell adenocarcinoma of the urethra?

It is a very rare type of cancer that starts in the urethra, the tube that carries urine out of the body. This case report focused on one woman with this condition.

What treatment did the patient receive?

She had surgery alone: laparoscopic radical cystectomy, lymph node dissection, and cutaneous ureterostomy. No chemotherapy or radiation was used.

How long did the patient survive without cancer?

The patient remained disease-free for 8 years after surgery, through January 2025. This is a very good outcome for this rare cancer.

Can this result be applied to other patients?

No, because this is a single case report. The findings may not apply to everyone with this cancer. More research is needed to see if surgery alone works for others.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
We report a 39-year-old woman with clear cell adenocarcinoma of the urethra (CCAU). She was treated with surgery alone and has survived 8 years without recurrence. The patient had painless hematuria. Imaging showed a 5.1 cm urethral mass. The tumor invaded the bladder and vagina (clinical stage T3N2M0). Urine cytology confirmed the diagnosis, which is unusual for CCAU. She underwent laparoscopic radical cystectomy, lymph node dissection, and cutaneous ureterostomy. Pathology showed clear cell adenocarcinoma with CK7+/PAX8+. The final pathological stage was T3N0M0. She did not receive adjuvant therapy. Follow-up through January 2025 (8 years) showed no tumor recurrence, which appears to be rare among reported cases.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.